|
|
Article: NewCo News: Cequent's RNAi Platform Draws Novartis Investment, Option.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Aiming to profit from the next step in RNA interference is Cequent Pharmaceuticals Corp., which last week closed a $9 million Series A financing, including an equity investment from the recently established Novartis Option Fund.
"We have $9 million in the bank [$3 million of that from Novartis], but all of the first-closing investors are committed to add another 50 percent of their original investment" when Cequent files its first investigational new drug application, said Peter Parker, president and CEO of Cambridge, Mass.-based Cequent. That filing will take place "hopefully, next year," he said.
Ampersand Ventures, Nexus ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|